Nortech Systems (NSYS) investor relations material

Executive summary

• Net sales rose 9.3% year-over-year to $33.5 million for Q2 2026, with gross margin improving to 17% and operating income at $623,000, driven by strong demand in Medical Device and Medical Imaging markets.

• Backlog remains strong, with a 90-day shipment backlog of $33.4 million (up 25.8% year-over-year) and total order backlog of $93.8 million (up 19.8% to 20%).

• Operational improvements stem from restructuring in 2024 and early 2025, enhanced manufacturing cost absorption, and increased production activity.

• Strategic focus on engineering innovation, sustainability, and supply chain resilience, including new leadership and proactive risk management.

• Net income for Q2 2026 was $316,000 ($0.11 per diluted share), nearly flat year-over-year.

Financial highlights

• Gross profit for Q2 2026 was $5.7 million, with gross margin at 17%, up 120 basis points year-over-year.

• Operating expenses increased to $5.1 million, mainly due to higher incentive and stock-based compensation.

• Operating income was $623,000 (1.9% of net sales), down from $742,000 in Q2 2025, but year-to-date operating income improved to $670,000 from a loss of $871,000.

• Adjusted EBITDA was $938,000, down 12.6% from $1.1 million in Q2 2025.

• Interest expense declined to $197,000 in Q2 2026 from $257,000 in Q2 2025.

Outlook and guidance

• Management expects continued sales momentum in 2026, supported by a strong backlog and stabilization in supply chain and customer orders.

• Focus remains on reducing inventory investments and generating cash from working capital reductions.

• Ongoing investment in people, technology, and regulatory expertise to drive future growth.

• Existing financing, cash flows, and cash on hand are considered sufficient for working capital, capital expenditures, and debt repayments for the next year.

• Management is focused on improving asset utilization and profitability in industrial and defense markets.